Blog
RSS FeedPosted by Michael Wonder on 12 Jul 2023
Ruzurgi is now available and covered by the vast majority of public health and private insurance plans
11 July 2023 - Médunik Canada is pleased to announce that Ruzurgi (amifampridine) is now covered by the vast majority of ...
Posted by Michael Wonder on 29 Jun 2023
Ontario to publicly reimburse Albrioza for the treatment of ALS
28 June 2023 - Ontario lists Albrioza on its drug benefit formulary, becoming the first province to publicly reimburse Albrioza, ...
Posted by Michael Wonder on 15 Jun 2023
Amylyx Pharmaceuticals completes negotiation process and signs letter of intent with the pCPA for Albrioza for the treatment of ALS
15 June 2023 - Amylyx will now work with federal, provincial, and territorial drug plans to ensure public coverage is available ...
Posted by Michael Wonder on 13 Jun 2023
Pilot expert committee to support decision-making across the drug life cycle
8 June 2023 - CADTH, Canada’s drug and health technology agency, announces the creation and inaugural membership of a new ...
Posted by Michael Wonder on 05 Jun 2023
Upcoming improvements to the CADTH reimbursement review process
5 June 2023 - Today, CADTH is communicating a series of improvements that will further our ambition to innovate in ...
Posted by Michael Wonder on 05 Jun 2023
Guidance for reporting real world evidence
31 May 2023 - CADTH has partnered with Health Canada, the Institut national d’excellence en santé et en services sociaux (INESSS), ...
Posted by Michael Wonder on 30 May 2023
Roche Canada and the pan-Canadian Pharmaceutical Alliance successfully complete negotiations for Vabysmo (faricimab injection) for the treatment of neovascular (wet) age-related macular degeneration and diabetic macular oedema
29 May 2023 - Roche Canada today announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance for ...
Posted by Michael Wonder on 18 May 2023
Collaboration creates roadmap in Canada to report real world evidence studies
16 May 2023 - CADTH, Health Canada, and the Institut national d’excellence en santé et en services sociaux (INESSS) are ...
Posted by Michael Wonder on 01 May 2023
Canada’s health minister denies interfering in agency’s efforts to lower drug costs
27 April 2023 - Health Minister Jean-Yves Duclos says he has not exercised any undue political pressure on the independent ...
Posted by Michael Wonder on 27 Apr 2023
CADTH, ICER, and NICE release joint position statement on redacting clinical data awaiting publication
24 April 2023 - The position statement is a step toward greater transparency of unpublished data and a tangible outcome ...
Posted by Michael Wonder on 27 Apr 2023
CADTH formalises offering on real-world evidence through its scientific advice program
25 April 2023 - During a 1-year learning period, CADTH expanded its Scientific Advice program to include advice on real-world evidence ...
Posted by Michael Wonder on 18 Apr 2023
AbbVie announces provincial reimbursement for Vraylar (cariprazine) for the treatment of schizophrenia in Québec
17 April 2023 - AbbVie today announced that Vraylat is now listed as an exception medication status on the list of ...
Posted by Michael Wonder on 02 Apr 2023
Mitsubishi Tanabe Pharma Canada receives engagement letter from Pan-Canadian Pharmaceutical Alliance for Radicava oral suspension
31 March 2023 - Mitsubishi Tanabe Pharma Canada is pleased to announce the company has entered into negotiations with the ...
Posted by Michael Wonder on 23 Mar 2023
Investments to support access to drugs for rare diseases
22 March 2023 - Today, the Government announced a total investment of up to $1.5 billion over three years in ...
Posted by Michael Wonder on 23 Mar 2023
Government of Canada improves access to affordable and effective drugs for rare diseases
22 March 2023 - Today, the Honourable Jean-Yves Duclos, Minister of Health, announced measures in support of the first-ever National Strategy ...